SCHEMBL4635939

SCHEMBL4635939

CC(C)OC(=O)c1cc(O)ccc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.53
DPP4 P27487 1/20 0.53
TYR P14679 4/20 0.52
SLC28A3 Q9HAS3 4/20 0.52
SLC5A1 P13866 1/20 0.52
SLC5A2 P31639 1/20 0.52
POLB P06746 2/20 0.51
GAA P10253 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
G6PD P11413 1/20 0.51
MAPK1 P28482 1/20 0.51
ADRA1A P35348 1/20 0.51
PTGS2 P35354 1/20 0.51
SNCA P37840 1/20 0.50
ACHE P22303 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7780208 0.91 SLC28A3 (0.50) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL4635319 0.91 SLC28A3 (0.55) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL7781036 0.90 SLC28A3 (0.49) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL7778446 0.89 SLC5A1 (0.48) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL7780430 0.89 SLC5A1 (0.48) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL7780226 0.89 SLC5A1 (0.48) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL7780183 0.89 TYR (0.49) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL4635652 0.87 SNCA (0.58) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL31131425 0.87 SLC28A3 (0.63) AKR1B1DPP4TYRSLC28A3SLC5A1
SCHEMBL7777981 0.87 SLC28A3 (0.50) AKR1B1DPP4TYRSLC28A3SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 AKR1B1 3154/4885DPP4 3179/4885TYR 149/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 AKR1B1 3102/4885DPP4 3158/4885TYR 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.